中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共2条，第1-2条 帮助

已选(0)清除 条数/页：   排序方式：
Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study 期刊论文
JOURNAL OF THORACIC ONCOLOGY, 2021, 卷号: 16
作者:  Fang, Y.;  Pan, H.;  Shou, J.;  Hong, W.;  Yang, X.;  Zhu, D.;  Zhou, Y.;  Lan, F.;  Rao, C.;  Chen, J.
收藏  |  浏览/下载：56/0  |  提交时间：2021/05/17
Anlotinib  NSCLC  anti-angiogenesis  
Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China 期刊论文
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021
作者:  Zhang, Xiangyu;  Zeng, Liang;  Li, Yizhi;  Xu, Qinqin;  Yang, Haiyan;  Lizaso, Analyn;  Mao, Xinru;  Jin, Ren'an;  Zeng, Yu;  Li, Qinglin;  Wang, Jianbo;  Li, Yang;  Zhang, Yongchang;  Yang, Nong
收藏  |  浏览/下载：56/0  |  提交时间：2021/03/15
Anlotinib  Immunotherapy  Programmed death 1 inhibitor  Lung cancer